Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Transactions
SEC Form 4 Filing
Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reported the exercise of stock options and sale of common stock on September 3, 2024, according to a Form 4 filing with the SEC.
Summary
- On September 3, 2024, Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options to acquire 1,667 shares of common stock at a price of $21.41 per share.
- Eydelman also sold a total of 1,543 shares of common stock in multiple transactions at prices ranging from $107.67 to $117.28 per share.
- Additionally, 2,203 shares were surrendered to cover tax withholding obligations related to the vesting of restricted stock units at a price of $110.15.
- Following these transactions, Eydelman directly owns 28,623 shares of Vaxcyte common stock and holds options for 179,997 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions executed under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's future prospects.
Future Outlook
The reporting person's future transactions will be governed by a pre-arranged Rule 10b5-1 trading plan.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Insider selling is a common occurrence in publicly traded companies, particularly after periods of stock appreciation.
- The use of 10b5-1 trading plans is a standard practice to avoid accusations of trading on inside information.
- The reported transactions are within the normal range for executive compensation and stock management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| June 29, 2023 | Date of adoption of Rule 10b5-1 trading plan. |
| April 1, 2023 | Initial vesting date for stock options (1/4 of shares). |
| September 3, 2024 | Date of stock option exercise and sales transactions. |
| September 4, 2024 | Date of Lock-Up Agreement. |
| September 5, 2024 | Date of Form 4 signature. |
| May 8, 2032 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.